Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone

May-Yun Wang, Roger H Unger

Research output: Contribution to journalArticlepeer-review

72 Scopus citations

Abstract

In obese rodents, excess myocardial lipid accumulation (lipotoxicity) of myocardium may cause cardiomyopathy that in the obese Zucker diabetic fatty (ZDF) fa/fa rat can be prevented by treatment with troglitazone (TGZ). To determine the underlying mechanisms, we measured total 5′-AMP-activated kinase (AMPK) protein and its activated, phosphorylated form, P-AMPK. P-AMPK was significantly reduced in both ZDF fa/fa rat and ob/ob mouse hearts compared with lean, wild-type controls. TGZ treatment of obese ZDF rats, which lowered cardiac lipid content, increased P-AMPK. Expression of protein phosphatase 2C (PP2C), which inactivates AMPK activity by dephosphorylation, was increased in untreated ZDF fa/fa rat hearts, but fell with TGZ treatment, suggesting that PP2C can influence AMPK activity. In cultured myocardiocytes, fatty acids reduced P-AMPK, suggesting a feed-forward effect of lipid overload. Our findings highlight a role of PP2C and AMPK in the derangements of cardiac lipid metabolism in obedity and provide new insights as to the mechanisms of the liporegulatory disorder leading to lipotoxic cardiomyopathy.

Original languageEnglish (US)
Pages (from-to)E216-E221
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume288
Issue number1 51-1
DOIs
StatePublished - Jan 2005

Keywords

  • Adenosine 5′-monophosphate-activated kinase
  • Diabetes
  • Heart
  • Obesity
  • Protein phosphatase 2C

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Physiology (medical)

Fingerprint Dive into the research topics of 'Role of PP2C in cardiac lipid accumulation in obese rodents and its prevention by troglitazone'. Together they form a unique fingerprint.

Cite this